Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.
Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024.
The company was incorporated in 2019 and is based in Palo Alto, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 28, 25 | -3.64 Increased by +69.80% | - |
| Nov 29, 24 | -0.82 Increased by +90.80% | - |
| Aug 1, 24 | -1.21 Increased by +88.97% | - |
| May 2, 24 | -6.08 Increased by +40.15% | - |
| Feb 8, 24 | -12.05 Decreased by -27.87% | - |
| Nov 2, 23 | -8.94 Increased by +21.51% | - |
| Aug 3, 23 | -11.00 Increased by +30.91% | - |
| May 4, 23 | -10.15 Increased by +35.60% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0.00 - | -3.47 M - | Decreased by N/A% - |